Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status

Clinical Lung Cancer

Volumn 8, Issue 2, 2006, Pages 130-134

  Lilenbaum, Rogerio C ^a   Huber, Rudolf M ^b   Treat, Joseph ^c   Masters, Gregory ^d   Kaubitzsch, Sabine ^e   Lane, Stephen ^f   Wissel, Paul ^f  

^a Mount Sinai Comprehensive Cancer Center   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e GLAXOSMITHKLINE   (Germany)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Antitumor activity; Palliative care; Pooled analysis

Indexed keywords

PLATINUM COMPLEX; TOPOTECAN;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MEDICAL RECORD REVIEW; NEUTROPENIA; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33750186662     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.041     Document Type: Article

References (33)

1. Page NC, Read WL, Tierney RM, et al. The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 2002; 21:305a (Abstract #1216).
2. Saijo N. Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer 2003; 89:2178-2183.
3. Chen TT, Chute JP, Feigal E, et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000; 92:1601-1607.
4. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794-1801.
5. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20:4665-4672.
6. Einhorn LH. Initial therapy with cisplarin plus VP-16 in small-cell lung cancer. Semin Oncol 1986; 13(suppl 3):5-9.
7. Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002; 23:225-239.
8. Kosmidis PA, Samatas E, Fountzilas G, et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Ontology Group for Lung Cancer Trials. Semin Oncol 1994; 21(suppl 6):23-30.
9. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002; 59:611-642.
10. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(suppl 1):3-13.
11. Gralla R.J. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004; 9(suppl 6):14-24.
12. Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003; CD001990.
13. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997; 27:158-165.
14. Kusumoto S, Koga K, Tsukino H, et al. Comparison of survival of patients with lung cancer between elderly (greater than or equal to 70) and younger (70 greater than) age groups. Jpn J Clin Oncol 1986; 16:319-323.
15. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46:4189-4194.
16. Sakuragi T, Oshita F, Nagashima S, et al. Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol 1996; 26:128-133.
17. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7:344-354.
18. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 2003; 55:1321-1330.
19. Grunberg SM, Crowley J, Hande KR, et al. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Ontology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 1999; 44:461-468.
20. Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years. J Clin Oncol 2004; 22:1872-1877.
21. Treat J, Huang CH, Lane SR, et al. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004; 9:173-181.
22. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-2096.
23. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtin ™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997; 18(suppl 1):35 (Abstract #126).
24. Eckardt J, Gralla R, Palmet MC, et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996; 7(suppl 5):107 (Abstract #513).
25. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
26. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
27. Huber RM, Reck M, Gosse H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small-cell lung cancer. Eur Respir J 2006; 27:1183-1189.
28. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
29. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
30. Osoba D, Murray N, Gelmon K, et al. Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. Oncology (Huntingt) 1994; 8:61-65.
31. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
32. Tan EH, Ang PT. Resolution of superior vena cava obstruction in small cell lung cancer patients treated with chemotherapy. Ann Acad Med Singapore 1995; 24:812-815.
33. Lilenbaum R. Management of advanced non-small-cell lung cancer in patients with a performance status of 2. Clin Lung Cancer 2004; 5:209-213.